MLL
IONS icon

Moody Lynn & Lieberson’s Ionis Pharmaceuticals IONS Stock Holding History

Moody Lynn & Lieberson’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,665
Closed -$403K – 210
2018
Q2 		$403K Buy
+9,665
New +$428K 0.05% 173

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Moody Lynn & Lieberson's IONS Position: Q3 2018 in Review

Moody Lynn & Lieberson sold out of Ionis Pharmaceuticals (IONS) in Q3 2018, closing a stake of 9,665 shares — an estimated $403K sold.

Moody Lynn & Lieberson first reported a position in IONS in Q2 2018 and held it in 1 quarter. The position peaked at $403K in Q2 2018. 322 funds tracked by Wall St. Rank hold IONS as of Q3 2018.

  • Moody Lynn & Lieberson reported no remaining Ionis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 9,665 Ionis Pharmaceuticals shares in Q3 2018, an estimated $403K.
  • Moody Lynn & Lieberson first reported a position in Ionis Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Ionis Pharmaceuticals position peaked at $403K in Q2 2018.
  • 322 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2018.

Based on Moody Lynn & Lieberson's 13F filing for Q3 2018, filed 29 Oct 2018.